FDA recall alert: Power Stick deodorants pulled from Walmart, Amazon over major manufacturing lapse — Is yours affected? Know here
This Power Stick deodorant recall is voluntary, and the exact breakup of the deodorants being recalled is as follows: 21,265 cases of Power Stick for Her Roll-on Antiperspirant Deodorant Powder Fresh, 22,482 cases of Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, and 23,467 cases of Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant.
The FDA recalled the Power Stick Deodorants for not following cGMP
The Power Stick Deodorants were recalled because they didn't follow Current Good Manufacturing Practices. Complying with these practices is intended to ensure that 'a product is safe for use, and that it has the ingredients and strength it claims to have.', per the FDA's own website.
A recall is underway for tens of thousands of cases of Power Stick antiperspirant deodorant, according to the Food and Drug Administration (FDA).An enforcement report published by the agency showed A.P. Deauville launched a recall for over 67,000 cases of "power fresh"-scented… pic.twitter.com/776p44qDH4
The FDA is among the most crucial regulatory agencies in the United States, and its ambit covers everything from food safety to over-the-counter pharmaceutical drugs, alongside vaccines and cosmetics, and grooming products such as deodorants.
The manufacturer of the recalled Power Stick Deodorants, A.P. Deauville, has not publicly spoken out about the recall.
The Power Stick deodorants were sold at major retailers nationwide
The recalled Power Stick Deodorants have been sold nationwide through various online and big box retail stores including Amazon, Walmart, and Dollar Tree. It's quite likely that these deodorants will have fallen into the hands of many Americans.
Due to the voluntary nature of the recall, it remains unclear whether all of the 67,000 deodorant sticks will find their way back to the retailers. The FDA has generally recommended that consumers either return any products marked for recall or simply discard them.
To stay updated on the stories that are going viral follow Indiatimes Trending.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Can cancer drugs treat Alzheimer's? New study thinks so
Alzheimer's disease, a progressive neurodegenerative disorder that primarily affects memory and cognitive functions, is the most common cause of dementia, accounting for 60-70% of dementia cases. As per Alzheimer's Association, in 2025, global Alzheimer's statistics indicate a significant prevalence of the disease, with projections estimating that over 7 million Americans will be living with Alzheimer's dementia. Globally, it is estimated that someone develops dementia every three seconds, and the number of people living with dementia is expected to reach 78 million by 2030. The progressive neurodegenerative disorder, long considered a therapeutic dead end, may soon find some hope of cure in an unlikely ally: cancer drugs. Recent research reveals that several oncology medications, originally designed to fight tumors, have shown promise in targeting key pathways of Alzheimer's disease (AD), from protein aggregation to neuroinflammation and metabolic dysfunction. Let's delve deeper into the newest discovery of the silver lining. The medical breakthrough: Scientists are exploring cancer drugs as a potential way to tackle Alzheimer's disease, given that the options for treatment are quite limited. As cases of Alzheimer's continue to rise in the U.S. and around the world due to an aging population, there still isn't a cure. Efforts to create new treatments that actually slow the disease's progression have mostly fallen short. Currently, only two drugs, Leqembi and Kisunla, are approved by the FDA to slow down early Alzheimer's, but their effectiveness is very limited. Many pharmaceutical companies have even stopped developing Alzheimer's drugs after unsuccessful trials, while others are experimenting with existing medications, including popular weight loss drugs. Researchers at the University of California, San Francisco, have taken a different approach. They searched through a database of over 1,300 various drugs, like antipsychotics and chemotherapy drugs, to find ones that could be repurposed for Alzheimer's treatment. Their study, published in the journal Cell , highlighted two cancer drugs that showed promise in reducing Alzheimer's risk. When tested together on mice, these drugs appeared to slow or even reverse Alzheimer's symptoms. One drug is typically used for breast cancer, and the other works against colon and lung cancer. Alzheimer's is known to cause significant changes in gene expression in the brain, which can disrupt brain function and lead to memory loss. From their database, fewer than 90 drugs successfully reversed markers related to Alzheimer's in human brain cells. Of these, five drugs seemed particularly effective in lowering Alzheimer's risk for actual patients, and the researchers focused on two FDA-approved cancer drugs to test in mice. According to the findings, letrozole, a breast cancer drug, appeared to influence gene expression in nerve cells, while irinotecan, used for colon and lung cancer, affected glial cells, which support the nervous system. Alzheimer's can damage nerve cells and trigger an overgrowth of glial cells, leading to brain inflammation. Interestingly, past studies have shown that breast cancer patients on letrozole had a lower chance of developing Alzheimer's, and colorectal cancer survivors treated with irinotecan also showed decreased risk, adding to the excitement around these findings. The groundbreaking findings: Researchers have been testing a combination of two cancer drugs in mice and found some promising results: the combo reversed brain degeneration and improved memory in mice showing signs of Alzheimer's. However, because what works in mice doesn't always work in humans, they plan to test these drugs in a clinical trial with Alzheimer's patients. Dr. Yadong Huang, a co-author of the study and a neurology professor at UCSF, noted the advantages of repurposing existing drugs: 'Developing a new drug can take hundreds of millions, or even billions, of dollars, and on average takes more than 10 years. For this repurposed drug, usually, it just takes two or three years, and then you can go to the clinical trial, and the cost is much, much lower.' Despite this progress, he acknowledged, as reported by NBC News, 'We still haven't generated or produced any very effective drugs that can really slow down dramatically the cognitive decline. ' Alzheimer's remains a complex disease, and its exact cause is still a mystery. Currently, it isn't clear why these cancer drugs might help with Alzheimer's. One idea is that the breast cancer drug reduces estrogen production, which controls many genes. Another theory is that the colon and lung cancer drug might reduce inflammation in the brain by stopping glial cells from multiplying. Dr. Melanie McReynolds, a biochemistry assistant professor at Pennsylvania State University, who wasn't involved in this study, added another angle. Her research suggests that another cancer drug can help Alzheimer's by regulating glucose metabolism, which is how cells generate energy. 'With aging, with stress, with diseases, that line of communication is disrupted,' she explained. She believes the drug combo could reverse metabolic decline, calling it 'the secret for contributing to better outcomes with Alzheimer's. ' What's ahead: Cancer drug repurposing opens a transformative chapter in Alzheimer's treatment, where repurposing anticancer agents allows researchers to exploit existing toxicity and pharmacokinetic data, potentially accelerating human testing and reducing development costs. While these findings are exciting, the potential side effects need to be carefully considered. Letrozole can cause hot flashes, and irinotecan may lead to severe diarrhea. 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota cautioned. 'It's not that it's a slam dunk.' Reduced risk of Alzheimer's disease linked to target protein for diabetes, as per a study
India Today
8 hours ago
- India Today
Children's Hospital LA halts use of Sarepta's gene therapy for all patients
Children's Hospital Los Angeles has paused the use of Sarepta Therapeutics' gene therapy Elevidys for all patients with muscular dystrophy, following recent US Food and Drug Administration (FDA) actions that raised safety a statement Monday, Children's Hospital LA said the pause has been communicated to affected patient families while it awaits any further determination by the FDA. The hospital is amongst more than 70 nationwide authorised to administer Elevidys. Five other major children's hospitals asked to comment on whether they planned to continue use of the gene therapy did not immediately respond, Reuters decision, effective July 18, comes after the FDA asked Sarepta last week to voluntarily halt shipments of the treatment. The request followed the death of a muscular dystrophy patient who received a different, experimental gene therapy. Sarepta has so far refused to comply, stating it will "continue making the treatment available to ambulatory patients." Elevidys was granted full FDA approval last year for children with Duchenne Muscular Dystrophy who can still walk, and received conditional approval for non-ambulatory patients. However, Sarepta suspended use in non-ambulatory cases in June, after two teenagers died of liver failure following FDA's recent request reignited scrutiny of the therapy's safety profile. Shares of Sarepta, down about 90% year-to-date, fell 5% on Monday to close at $13.32 on Nasdaq.- EndsWith inputs from Reuters
Hindustan Times
12 hours ago
- Hindustan Times
Over 67,000 cases of deodorant sold at Walmart, Amazon recalled. What to know
Keeping your armpits fresh just got a little more complicated. Late last week, the FDA issued a national recall for more than 67,000 cases of Power Stick deodorants after uncovering serious manufacturing problems. According to a report by The Cut, the products are made by A.P. Deauville, a Pennsylvania-based company that produces personal care goods sold at major retailers across the country. The FDA says the recall was prompted by violations of current good manufacturing practices (cGMP) - a legal set of standards companies must follow to ensure product safety.(Representative Image/Pixabay) Also read: Power Stick deodorant recall: Why thousands of units sold at Walmart, Dollar Tree, and Amazon have been recalled Why were Power Stick deodorants recalled? The FDA says the recall was prompted by violations of current good manufacturing practices (cGMP)—a legal set of standards companies must follow to ensure product safety. But the agency did not offer specifics. The reason behind this could be a contamination issue, mislabeling, or something else entirely; the FDA has yet to share it. But the reason was enough for the FDA to pull tens of thousands of deodorant bottles off the shelves. Also read: Lois Boisson breaks silence on Harriet Dart's bizarre 'deodorant' remark as fans express outrage The affected items include: Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Power Stick Invisible Protection Roll-On Spring Fresh Power Stick for Her Roll-On Powder Fresh The deodorants have been sold widely through retailers like Amazon, Walmart, and Dollar Tree, so check your bathroom cabinet if you have picked one up lately. The FDA is advising anyone who purchased a recalled item to either throw it out or return it to the store, according to The Cut. This is not the first instance of issues with deodorants. According to the reports, recently, there has been a viral panic over aluminium and cancer. FAQs: 1. Why were Power Stick deodorants recalled? The FDA flagged issues with how the deodorants were manufactured, citing violations of safety standards, but didn't specify the exact problem. 2. Which Power Stick products are affected? Three roll-on versions are part of the recall: Original Nourishing Invisible Protection, Spring Fresh, and Powder Fresh for Her. 3. Where were the recalled deodorants sold? They were sold nationwide at stores like Amazon, Walmart, and Dollar Tree. 4. What should I do if I bought one? You should stop using it immediately and either return it to the store or dispose of it safely. 5. Are recalled deodorants dangerous to use? The FDA hasn't detailed the risk, but recalls usually mean there's a potential health or safety concern, so it's best not to use them.
